NEW YORK (360Dx) – Celcuity said after the close of the markets on Tuesday that it will work with Puma Biotechnology in a Phase II clinical trial.

As part of the deal, West Cancer Center will be the sponsor and principal investigator on the trial, which will use Celcuity's CELx HER2 Signaling Function test to evaluate the efficacy and safety of Puma Bio's Nerlynx (neratinib) and chemotherapy on patients with early-stage triple-negative breast cancer. Up to 27 patients will be part of the trial, the partners said.